Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Bristol-Myers Squibb Co's Net Cash per Share or its related term are showing as below:
XSWX:BMY's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 8.78 * Ranked among companies with meaningful Price-to-Net-Cash only.
Bristol-Myers Squibb Co (XSWX:BMY) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Bristol-Myers Squibb Co Net Cash per Share Related Terms
Bristol-Myers Squibb Co Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Bristol-Myers Squibb Co's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BMY vs PFE, GILD, AMGN: Net Cash per Share Comparison
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co Price-to-Net-Cash vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's Price-to-Net-Cash falls into.
Bristol-Myers Squibb Co Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Bristol-Myers Squibb Co's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co (XSWX:BMY) has a Net Cash per Share of CHF-21.23 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Bristol-Myers Squibb Co and its competitors. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #999999 out of 253 companies in the Drug Manufacturers industry.
Is Bristol-Myers Squibb Co's Net Cash per Share too high?
Bristol-Myers Squibb Co's current Net Cash per Share is CHF-21.23. Based on the distribution chart, Bristol-Myers Squibb Co ranks #999999 out of 253 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bristol-Myers Squibb Co has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Net Cash per Share compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #999999 out of 253 companies for Net Cash per Share. This places Bristol-Myers Squibb Co in the lower half of its industry. The industry median Net Cash per Share is 8.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Drug Manufacturers company?
The median Net Cash per Share among Drug Manufacturers companies is 8.78, based on 253 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Bristol-Myers Squibb Co and its competitors. For the Drug Manufacturers industry, the median Net Cash per Share is 8.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bristol-Myers Squibb Co's current Net Cash per Share is CHF-21.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (XSWX:BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF45.75, compared to a current price of CHF54.34 — trading 18.8% above its estimated fair value. The current Net Cash per Share is CHF-21.23. Bristol-Myers Squibb Co's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Bristol-Myers Squibb Co (XSWX:BMY), the current Net Cash per Share is CHF-21.23 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (XSWX:BMY) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of CHF54.34 is trading 18.8% above its estimated GF Value™ of CHF45.75.
GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.
Key valuation signals for XSWX:BMY:
Net Cash per Share: CHF-21.23
GF Value™: CHF45.75 vs. price of CHF54.34 (18.8% above fair value)
No single metric tells the full story. See the XSWX:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
73GF Score
Get the complete analysis for XSWX:BMY
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BMY has been successfully added to your 
